METiS TechBio, an AI-driven drug design startup, saw its shares surge 173% on its Hong Kong debut, driven by strong investor demand for AI-related stocks. The company utilizes artificial intelligence to develop nano-rockets for drug delivery.

Shares of METiS TechBio surged 173 per cent on their Hong Kong debut on Wednesday as the AI-driven drug design start-up’s initial public offering drew strong demand from investors amid buoyant sentiment for AI-related stocks in the city. Its stocks first traded at HK$28.68, significantly higher than its offering price of HK$10.50 each. Co-founder and CEO of METiS TechBio, Lai Tsai-Ta, who obtained a PhD from the Massachusetts Institute of Technology in the US, said artificial intelligence had...